Literature DB >> 14761931

Microalbuminuria as a marker of cardiovascular and renal risk in type 2 diabetes mellitus: a temporal perspective.

James T Lane1.   

Abstract

Microalbuminuria is a marker for diabetic nephropathy. It also signifies cardiovascular disease, as well as nephropathy, in type 2 diabetes (DM2). Microalbuminuria may precede DM2, occurring with the insulin resistance syndrome and its components, including obesity and hypertension. Other indicators of cardiovascular risk, such as markers of inflammation, are associated with microalbuminuria in populations of patients with and without diabetes. With the rising prevalence of DM2 in minority youth, especially in Native Americans, a marker for future disease risk would allow earlier prevention strategies to be tested. Before microalbuminuria can be used in a prevention strategy, more needs to be known about the mechanism(s) of the association between elevated excretion, its relationship to glucose intolerance, and its relative contribution to cardiovascular and renal disease. These questions are especially applicable as we begin to observe the long-term complications of diabetes in youth.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14761931     DOI: 10.1152/ajprenal.00247.2003

Source DB:  PubMed          Journal:  Am J Physiol Renal Physiol        ISSN: 1522-1466


  21 in total

Review 1.  The link between the renin-angiotensin-aldosterone system and renal injury in obesity and the metabolic syndrome.

Authors:  Tina Thethi; Masumi Kamiyama; Hiroyuki Kobori
Journal:  Curr Hypertens Rep       Date:  2012-04       Impact factor: 5.369

2.  Predictive impact of elevated serum level of IL-18 for early renal dysfunction in type 2 diabetes: an observational follow-up study.

Authors:  S Araki; M Haneda; D Koya; T Sugimoto; K Isshiki; M Chin-Kanasaki; T Uzu; A Kashiwagi
Journal:  Diabetologia       Date:  2007-01-16       Impact factor: 10.122

Review 3.  Type 2 diabetes and cardiovascular disease: Have all risk factors the same strength?

Authors:  Iciar Martín-Timón; Cristina Sevillano-Collantes; Amparo Segura-Galindo; Francisco Javier Del Cañizo-Gómez
Journal:  World J Diabetes       Date:  2014-08-15

4.  Proteinuria and renal disease: prognostic value of urine dipstick testing for leukocytes.

Authors:  Shira Koss; Ari Perl; Adinah Wieder; Rachel Frank; Suzanne Vento; Howard Trachtman
Journal:  Pediatr Nephrol       Date:  2006-03-01       Impact factor: 3.714

Review 5.  Effects of polyunsaturated fatty acid consumption in diabetic nephropathy.

Authors:  Haim Shapiro; Miryam Theilla; Joelle Attal-Singer; Pierre Singer
Journal:  Nat Rev Nephrol       Date:  2010-12-07       Impact factor: 28.314

Review 6.  Metabolic syndrome therapy: prevention of vascular injury by antidiabetic agents.

Authors:  Ligia J Dominguez; James R Sowers
Journal:  Curr Hypertens Rep       Date:  2005-04       Impact factor: 5.369

Review 7.  Clinical therapeutic strategies for early stage of diabetic kidney disease.

Authors:  Munehiro Kitada; Keizo Kanasaki; Daisuke Koya
Journal:  World J Diabetes       Date:  2014-06-15

8.  Development of multiple complications in type 2 diabetes is associated with the increase of multiple markers of chronic inflammation.

Authors:  Jawl-Shan Hwang; Tsu-Lan Wu; S C Chou; C Ho; Pi-Yueh Chang; Kuo-Chien Tsao; Jeng-Yi Huang; Chien-Feng Sun; James T Wu
Journal:  J Clin Lab Anal       Date:  2008       Impact factor: 2.352

9.  Simvastatin reverses podocyte injury but not mesangial expansion in early stage type 2 diabetes mellitus.

Authors:  P Wei; P R Grimm; D C Settles; C R Balwanz; B J Padanilam; S C Sansom
Journal:  Ren Fail       Date:  2009       Impact factor: 2.606

10.  Possible Link between Metabolic Syndrome and Chronic Kidney Disease in the Development of Cardiovascular Disease.

Authors:  Kosaku Nitta
Journal:  Cardiol Res Pract       Date:  2010-10-07       Impact factor: 1.866

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.